Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
PD-1/PD-L1 immune-checkpoint inhibitors in glioblastoma: A concise review.
|
30819441 |
2019 |
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we developed a cyclic peptide iRGD (CCRGDKGPDC)-conjugated solid lipid nanoparticle (SLN) to deliver small interfering RNAs (siRNAs) against both epidermal growth factor receptor (EGFR) and PD-L1 for combined targeted and immunotherapy against glioblastoma, the most aggressive type of brain tumors.
|
30916923 |
2019 |
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Myeloid-Derived Suppressive Cells Promote B cell-Mediated Immunosuppression via Transfer of PD-L1 in Glioblastoma.
|
31530559 |
2019 |
Adult Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
PD-L1 expression on glioblastoma surface promotes PD-1 receptor activation in microglia, resulting in the negative regulation of T cell responses.
|
31661771 |
2019 |
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Multiplexed immunophenotyping was used to identify PD-L1+ cell populations in post-treatment glioblastoma.
|
30011045 |
2019 |
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results indicate that anti-PD-L1 immunotherapy enhances a radiation induced abscopal response via canonical T-cell activation and direct macrophage activation in glioblastoma.
|
31793634 |
2019 |
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Importantly, pevonedistat attenuates T cell killing through PD-L1 induction, and blockade of PD-L1 restores the sensitivity of pevonedistat-treated glioblastoma cancer cells to T cell killing.
|
31044422 |
2019 |
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this review, we describe the immunosuppressive molecular characteristics of the tumour microenvironment (TME), candidate biomarkers of PD-1/PD-L1 checkpoint blockades, ongoing clinical trials and challenges of PD-1/PD-L1 checkpoint blockades in glioblastoma.
|
30777100 |
2019 |
Adult Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Growth and differentiation factor 15 regulates PD-L1 expression in glioblastoma.
|
31114328 |
2019 |
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, our data proposes poly(I:C) treatment combined with PD-L1 blockade to invigorate the immune checkpoint inhibition response in glioblastoma.
|
29399410 |
2018 |
Adult Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Correlation between lower balance of Th2 helper T-cells and expression of PD-L1/PD-1 axis genes enables prognostic prediction in patients with glioblastoma.
|
29721184 |
2018 |
Adult Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
PD-L1 expression correlated with the mesenchymal transcriptome profile and was anatomically localized in the perinecrotic and pseudopalisading niche of human glioblastoma specimens.
|
29532035 |
2018 |
Adult Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Glioblastoma stem cell-derived exosomes induce M2 macrophages and PD-L1 expression on human monocytes.
|
29632728 |
2018 |
Adult Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The effects of GMCI on PD ligand 1 (PD-L1) expression in glioblastoma were investigated in vitro and in vivo.
|
29016938 |
2018 |
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The immune checkpoint protein PD-L1 induces and maintains regulatory T cells in glioblastoma.
|
29900065 |
2018 |
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma.
|
28115578 |
2017 |
Adult Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We used D54 and U251 glioblastoma cell lines that constitutively expressed PD-L1.
|
28978117 |
2017 |
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Non-tumor cell IDO1 predominantly contributes to enzyme activity and response to CTLA-4/PD-L1 inhibition in mouse glioblastoma.
|
28179106 |
2017 |
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study was designed to clarify the change of the molecular expression, including programmed cell death 1 (PD-1) and PD-ligand 1 (PD-L1), on the initial and secondary resected tumor specimens and to address the influence of these expressions for patient outcome after second surgery of glioblastoma.
|
28447277 |
2017 |
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In summary, the ongoing clinical studies evaluating the activity of PD-1/PD-L1 inhibitors in glioblastoma need to be complemented with well designed and stringently executed studies to understand the influence of PD-1/PD-L1 expression on therapy response or failure and to develop robust means of PD-L1 assessment for meaningful biomarker development.
|
26501438 |
2016 |
Adult Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
PD-L1 expression and prognostic impact in glioblastoma.
|
26323609 |
2016 |
Adult Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
PD-L1 expression by neurons nearby tumors indicates better prognosis in glioblastoma patients.
|
23986257 |
2013 |
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Distinct effects of human glioblastoma immunoregulatory molecules programmed cell death ligand-1 (PDL-1) and indoleamine 2,3-dioxygenase (IDO) on tumour-specific T cell functions.
|
20493562 |
2010 |